Thrombosis study inpatients with end stage renal disease,” Circulation, vol. 124, no. 21, supplement, p. A13303, 2011. [33] J. van Ryn, M. Neubauer, R. Flieg et al., “Successful removal of dabigatran in ﬂowing blood with an activated charcoal hemoperfusion column in an in vitro test system (abstract P485),” Pathophysiology of Haemostasis and Thrombosis, vol. 57, p. A94, 2010. [34] PHARMAC The Pharmaceutical Management Agency of New Zealand, “Guidelines for management of bleeding with dabigatran,” 2011, http://www.pharmac.govt.nz/2011/06/13/ Dabigatran%20bleeding%20management.pdf. [35] J. S. Healey, J. Eikelboom, J. Douketis et al., “Peri-procedural bleeding and thromboembolic events with dabigatran com- pared to warfarin. Results from the RE-LY trial,” Circulation, vol. 124, no. 21, supplement, p. A12041, 2011. [36] J. D. Douketis, A. C. Spyropoulos, F. A. Spencer et al., “Peri- operative management of antithrombotic therapy: antithrom- botic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, supplement 2, pp. e326S–e350S, 2012. [37] L. Green and S. J. MacHin, “Managing anticoagulated patients during neuraxial anaesthesia,” British Journal of Haematology, vol. 149, no. 2, pp. 195–208, 2010. [38] E. Vandermeulen, “Is anticoagulation and central neural blockade a safe combination?” Current Opinion in Anaesthe- siology, vol. 12, no. 5, pp. 539–543, 1999. [39] T. Horlocker, D. Wedel, J. Rowlingson et al., “American College of Chest Physicians. Executive summary: regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy. American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (third edition),” Regional Anesthesia and Pain Medicine, vol. 35, pp. 64–101, 2010. [40] N. Rosencher, M. P. Bonnet, and D. I. Sessler, “Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies,” Anaesthesia, vol. 62, no. 11, pp. 1154–1160, 2007. [41] J. Stangier, K. Rathgen, H. Sthle, and D. Mazur, “Inﬂuence of renal impairment on the pharmacokinetics and pharmaco- dynamics of oral dabigatran etexilate: an open-label, parallel- group, single-centre study,” Clinical Pharmacokinetics, vol. 49, no. 4, pp. 259–268, 2010. [42] A. L. Dans, S. Connolly, and M. Brueckmann, “Concom- itant use of antiplatelet therapy with dabigatran or warfa- rin in the randomized evaluation of long-term anticoa- gulation therapy (RE-LY) trial,” Presented at the Euro- pean Society of Cardiology Congress, 2011, http://www.esca- rdio.org/congresses/esc-2011/congress-reports/Pages/709-5- RE-LY.aspx. [43] J. W. Eikelboom, L. Wallentin, S. J. Connolly et al., “Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial ﬁbrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial,” Circulation, vol. 123, no. 21, pp. 2363– 2372, 2011. [44] S. D. Wiviott, E. Braunwald, C. H. McCabe et al., “Prasugrel versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 357, no. 20, pp. 2001–2015, 2007. [45] L. Wallentin, R. C. Becker, A. Budaj et al., “Ticagrelor versus clopidogrel in patients with acute coronary syndromes,” The New England Journal of Medicine, vol. 361, no. 11, pp. 1045– 1057, 2009. 9 [46] J. S. Paikin, D. S. Wright, M. A. Crowther, S. R. Mehta, and J. W. Eikelboom, “Triple antithrombotic therapy in patients with atrial ﬁbrillation and coronary artery stents,” Circulation, vol. 121, no. 18, pp. 2067–2070, 2010. [47] Boehringer Ingelheim, RELY-ABLE Trial Emergency Infor- mation, 2011, http://www.rely-able-trial.com/Rely2Web/ resources/jsp/emerency sub menu.jsp. [48] F. van de Werf, J. Bax, A. Betriu et al., “Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology,” European Heart Journal, vol. 29, pp. 2909–2945, 2008. [49] R. S. Wright, J. L. Anderson, C. D. Adams et al., “2011 ACCF/AHA focused update of the guidelines for the man- agement of patients with unstable angina/non-ST-elevation myocardial infarction (Updating the 2007 Guideline): a report of the American College of cardiology foundation/American heart association task force on practice guidelines,” Circula- tion, vol. 123, no. 18, pp. 2022–2060, 2011. [50] C. W. Hamm, J. P. Bassand, S. Agewall et al., “ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC),” European Heart Journal, vol. 32, pp. 2999–3054, 2011. [51] S. J. Connolly, M. D. Ezekowitz, S. Yusuf, P. A. Reilly, and L. Wallentin, “Newly identiﬁed events in the RE-LY trial,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1875– 1876, 2010. [52] S. H. Hohnloser, J. Oldgren, S. Yang et al., “Myocardial ischemic events in patients with atrial ﬁbrillation treated with dabigatran or warfarin in the RE-LY Trial,” Circulation, vol. 125, pp. 669–676, 2012. [53] G. Y. H. Lip and D. A. Lane, “Does warfarin for stroke thromboprophylaxis protect against MI in atrial ﬁbrillation patients?” The American Journal of Medicine, vol. 123, no. 9, pp. 785–789, 2010. [54] K. Uchino and A. V. Hernandez, “Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials,” Archives of Internal Medicine, vol. 172, no. 5, pp. 397–402, 2012. [55] G. W. Barsness, J. S. Smith, B. I. Eriksson et al., “Evaluation of the acute coronary syndrome safety proﬁle of dabigatran etexilate in patients undergoing major orthopedic surgery,” Circulation, vol. 124, no. 21, supplement, p. A14413, 2011. [56] J. Eikelboom, J. Oldgren, and P. Reilly, “No evidence of platelet activation in patients with atrial ﬁbrillation who are treated with dabigatran: a substudy of the RELY Trial,” in Proceedings of the International Society on Thrombosis and Haemostasis, July 2011. [57] R. A. Winkle, R. H. Mead, G. Engel et al., “The use of dabigatran immediately after atrial ﬁbrillation ablation,” Journal of Cardiovascular Electrophysiology, vol. 23, no. 3, pp. 264–268, 2012. [58] ClinicalTrials.gov, “DAPPAR AF,” 2011, http://clinicaltrials .gov/ct2/show/NCT01468155?term=dappar&rank=1. [59] R. Nagarakanti, M. D. Ezekowitz, J. Oldgren et al., “Dabigatran versus warfarin in patients with atrial ﬁbrillation: an analysis of patients undergoing cardioversion,” Circulation, vol. 123, no. 2, pp. 131–136, 2011. [60] A. de Smedt, S. de Raedt, K. Nieboer, J. de Keyser, and R. Brouns, “Intravenous thrombolysis with recombinant